Incyte Corporation Q2 2025 Financial Results

Incyte Corporation reported its financial results for the second quarter of 2025, showing significant growth in total revenues, which increased by 16% year-over-year to $1.216 billion. The company's product revenues also saw a strong increase, rising by 17% to $1.059 billion. Key drivers of this growth included Jakafi, which generated $764 million in net product revenues, an 8% increase from the previous year, and Opzelura, which saw a 35% increase in net product revenues to $164 million. Additionally, Niktimvo, a newly launched product, contributed $36 million in net product revenues. The company also announced regulatory milestones, including the approval of Zynyz for squamous cell anal carcinoma and Monjuvi for follicular lymphoma. Incyte raised its full-year 2025 guidance for Jakafi to a new range of $3.000 - $3.050 billion and for other oncology products to $500 - $520 million. The company's financial performance was further bolstered by a settlement agreement with Novartis, which reduced future royalty payments on Jakafi.